Society News

Are you in need of a new headshot for your website or institution’s site? Good news for you! Attendees can get a professional head shot taken from 10am to 2pm on Thursday and Friday at the Vascular Annual Meeting. Stop by the SVS Member Booth, #331, in the Exhibit Hall to take advantage of the opportunity! SVS reserves the right to use the photos, but you may use them however you’d like. Still need to register for the meeting? Do so today.

Are you in need of a new headshot for your website or institution’s site? Good news for you! Attendees can get a professional head shot taken from 10am to 2pm on Thursday and Friday at the Vascular Annual Meeting. Stop by the SVS Member Booth, #331, in the Exhibit Hall to take advantage of the opportunity! SVS reserves the right to use the photos, but you may use them however you’d like. Still need to register for the meeting? Do so today.

Are you in need of a new headshot for your website or institution’s site? Good news for you! Attendees can get a professional head shot taken from 10am to 2pm on Thursday and Friday at the Vascular Annual Meeting. Stop by the SVS Member Booth, #331, in the Exhibit Hall to take advantage of the opportunity! SVS reserves the right to use the photos, but you may use them however you’d like. Still need to register for the meeting? Do so today.

Many fabulous prizes are now available for bidding. The Society for Vascular Surgery has compiled nearly 70 packages for items graciously donated for the silent auction portion of the ‘Vascular Spectacular’ gala. The event takes place at the Vascular Annual Meeting on Friday, June 14, in National Harbor, MD. Everyone, including non-attendees, may participate in the silent auction until it closes during the gala itself. Sign up to participate in the auction here.

Many fabulous prizes are now available for bidding. The Society for Vascular Surgery has compiled nearly 70 packages for items graciously donated for the silent auction portion of the ‘Vascular Spectacular’ gala. The event takes place at the Vascular Annual Meeting on Friday, June 14, in National Harbor, MD. Everyone, including non-attendees, may participate in the silent auction until it closes during the gala itself. Sign up to participate in the auction here.

Many fabulous prizes are now available for bidding. The Society for Vascular Surgery has compiled nearly 70 packages for items graciously donated for the silent auction portion of the ‘Vascular Spectacular’ gala. The event takes place at the Vascular Annual Meeting on Friday, June 14, in National Harbor, MD. Everyone, including non-attendees, may participate in the silent auction until it closes during the gala itself. Sign up to participate in the auction here.

Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org/discussions) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses.

In case you missed it, here are the most popular clinical discussions shared in the forum recently:
 

1. Perianal fistula found in UC patient (http://ow.ly/S8bJ30okWuO)

A 20-year-old male patient with no previous medical history was seen and treated last year for pancolitis. His physician solicits drug therapy preferences from the GI community, given the age of the patient and a newly discovered perianal fistula.

2. IBD patient with risk of cancer (http://ow.ly/KoGz30oHdjG)

A 62-year-old female patient with a long history of Crohn’s disease developed acute hepatitis. She had a colectomy in 2011 where a one-stage ileo rectal anastomosis was performed instead of a J-pouch. She was in remission under surveillance and mesalamine, until recently. She also has primary sclerosing cholangitis (PSC) and multifocal dysplasia, a combination that raised concern among the GI community about the patient’s risk of cancer.

3. Significant daily pain in Crohn’s patient (http://ow.ly/FHUI30oHdI8)

A recent colonoscopy for a 39-year-old man with Crohn’s disease revealed active disease in the ileum and sigmoid colon with narrowing at the recto-sigmoid colon. The MRE revealed active inflammation at the ileo-colonic anastomosis and of the sigmoid and descending colon, with no noted fistulas. His physician solicits advice in the forum on next steps for the patient, who was experiencing significant pain daily, despite being on a low residue diet and consistent drug therapy.

Other popular clinical discussions:

• WATS imaging in Barrett’s esophagus (http://ow.ly/PrJ330oHdCN)

Members share their opinions and experiences with Wide-Area Transepithelial Sampling (WATS) in Barrett’s esophagus (BE) after mention of recent data demonstrating its promising potential for surveillance in BE patients, despite not yet being approved by the FDA.



• Positive FIT with negative colonoscopy (http://ow.ly/zSxC30oHcZM)

A physician solicits advice on next steps in managing average-risk patients with a positive FIT and negative colonoscopy screening, and asks colleagues if their actions would change after discovering a patient also had non-bleeding hemorrhoids on exam.

More clinical cases and discussions are at https://community.gastro.org/discussions.


 

Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org/discussions) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses.

In case you missed it, here are the most popular clinical discussions shared in the forum recently:
 

1. Perianal fistula found in UC patient (http://ow.ly/S8bJ30okWuO)

A 20-year-old male patient with no previous medical history was seen and treated last year for pancolitis. His physician solicits drug therapy preferences from the GI community, given the age of the patient and a newly discovered perianal fistula.

2. IBD patient with risk of cancer (http://ow.ly/KoGz30oHdjG)

A 62-year-old female patient with a long history of Crohn’s disease developed acute hepatitis. She had a colectomy in 2011 where a one-stage ileo rectal anastomosis was performed instead of a J-pouch. She was in remission under surveillance and mesalamine, until recently. She also has primary sclerosing cholangitis (PSC) and multifocal dysplasia, a combination that raised concern among the GI community about the patient’s risk of cancer.

3. Significant daily pain in Crohn’s patient (http://ow.ly/FHUI30oHdI8)

A recent colonoscopy for a 39-year-old man with Crohn’s disease revealed active disease in the ileum and sigmoid colon with narrowing at the recto-sigmoid colon. The MRE revealed active inflammation at the ileo-colonic anastomosis and of the sigmoid and descending colon, with no noted fistulas. His physician solicits advice in the forum on next steps for the patient, who was experiencing significant pain daily, despite being on a low residue diet and consistent drug therapy.

Other popular clinical discussions:

• WATS imaging in Barrett’s esophagus (http://ow.ly/PrJ330oHdCN)

Members share their opinions and experiences with Wide-Area Transepithelial Sampling (WATS) in Barrett’s esophagus (BE) after mention of recent data demonstrating its promising potential for surveillance in BE patients, despite not yet being approved by the FDA.



• Positive FIT with negative colonoscopy (http://ow.ly/zSxC30oHcZM)

A physician solicits advice on next steps in managing average-risk patients with a positive FIT and negative colonoscopy screening, and asks colleagues if their actions would change after discovering a patient also had non-bleeding hemorrhoids on exam.

More clinical cases and discussions are at https://community.gastro.org/discussions.


 

Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org/discussions) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses.

In case you missed it, here are the most popular clinical discussions shared in the forum recently:
 

1. Perianal fistula found in UC patient (http://ow.ly/S8bJ30okWuO)

A 20-year-old male patient with no previous medical history was seen and treated last year for pancolitis. His physician solicits drug therapy preferences from the GI community, given the age of the patient and a newly discovered perianal fistula.

2. IBD patient with risk of cancer (http://ow.ly/KoGz30oHdjG)

A 62-year-old female patient with a long history of Crohn’s disease developed acute hepatitis. She had a colectomy in 2011 where a one-stage ileo rectal anastomosis was performed instead of a J-pouch. She was in remission under surveillance and mesalamine, until recently. She also has primary sclerosing cholangitis (PSC) and multifocal dysplasia, a combination that raised concern among the GI community about the patient’s risk of cancer.

3. Significant daily pain in Crohn’s patient (http://ow.ly/FHUI30oHdI8)

A recent colonoscopy for a 39-year-old man with Crohn’s disease revealed active disease in the ileum and sigmoid colon with narrowing at the recto-sigmoid colon. The MRE revealed active inflammation at the ileo-colonic anastomosis and of the sigmoid and descending colon, with no noted fistulas. His physician solicits advice in the forum on next steps for the patient, who was experiencing significant pain daily, despite being on a low residue diet and consistent drug therapy.

Other popular clinical discussions:

• WATS imaging in Barrett’s esophagus (http://ow.ly/PrJ330oHdCN)

Members share their opinions and experiences with Wide-Area Transepithelial Sampling (WATS) in Barrett’s esophagus (BE) after mention of recent data demonstrating its promising potential for surveillance in BE patients, despite not yet being approved by the FDA.



• Positive FIT with negative colonoscopy (http://ow.ly/zSxC30oHcZM)

A physician solicits advice on next steps in managing average-risk patients with a positive FIT and negative colonoscopy screening, and asks colleagues if their actions would change after discovering a patient also had non-bleeding hemorrhoids on exam.

More clinical cases and discussions are at https://community.gastro.org/discussions.


 

Recognition is increasing among GI practitioners about the influence of nutrition and diet on patient outcomes. From irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), celiac, mast cell activation syndrome, and other maladies, what patients consume plays a role in how well they combat these diseases. Increasingly, clinicians are working with allied health professionals including allergists, nutritionists, and dietitians to forge partnerships to promote sound gut health. In response to this growing trend, the 2019 James W. Freston Conference – Food at the Intersection of Gut Health and Disease, Aug. 9-10, 2019, in Chicago, will examine how nutrition management therapies can combat GI disorders and how diet supports improvement across the care continuum.

Since 2008, Freston has focused on single-issue topics where experts gather to address practitioner challenges and solutions as well as gastroenterological science. Following this year’s Freston, attendees will leave with a deep understanding about:

• How to recognize and differentiate food-induced GI disorders.

• Diets that promote sound gut health care.

• How nutrient-gene interactions may alter gastrointestinal conditions.

• How nutrition can help patients with gastroesophageal reflux disease (GERD), IBS, IBD, FGIDs and mast cell activation syndrome.

• Implementing nutrition management therapies.

Join like-minded practitioners and industry counterparts in Freston’s intimate environment designed to foster learning, networking, and engagement. Registration is open and early bird rates are in effect through June 5. Learn more by visiting freston.gastro.org

[email protected]

Recognition is increasing among GI practitioners about the influence of nutrition and diet on patient outcomes. From irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), celiac, mast cell activation syndrome, and other maladies, what patients consume plays a role in how well they combat these diseases. Increasingly, clinicians are working with allied health professionals including allergists, nutritionists, and dietitians to forge partnerships to promote sound gut health. In response to this growing trend, the 2019 James W. Freston Conference – Food at the Intersection of Gut Health and Disease, Aug. 9-10, 2019, in Chicago, will examine how nutrition management therapies can combat GI disorders and how diet supports improvement across the care continuum.

Since 2008, Freston has focused on single-issue topics where experts gather to address practitioner challenges and solutions as well as gastroenterological science. Following this year’s Freston, attendees will leave with a deep understanding about:

• How to recognize and differentiate food-induced GI disorders.

• Diets that promote sound gut health care.

• How nutrient-gene interactions may alter gastrointestinal conditions.

• How nutrition can help patients with gastroesophageal reflux disease (GERD), IBS, IBD, FGIDs and mast cell activation syndrome.

• Implementing nutrition management therapies.

Join like-minded practitioners and industry counterparts in Freston’s intimate environment designed to foster learning, networking, and engagement. Registration is open and early bird rates are in effect through June 5. Learn more by visiting freston.gastro.org

[email protected]

Recognition is increasing among GI practitioners about the influence of nutrition and diet on patient outcomes. From irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), celiac, mast cell activation syndrome, and other maladies, what patients consume plays a role in how well they combat these diseases. Increasingly, clinicians are working with allied health professionals including allergists, nutritionists, and dietitians to forge partnerships to promote sound gut health. In response to this growing trend, the 2019 James W. Freston Conference – Food at the Intersection of Gut Health and Disease, Aug. 9-10, 2019, in Chicago, will examine how nutrition management therapies can combat GI disorders and how diet supports improvement across the care continuum.

Since 2008, Freston has focused on single-issue topics where experts gather to address practitioner challenges and solutions as well as gastroenterological science. Following this year’s Freston, attendees will leave with a deep understanding about:

• How to recognize and differentiate food-induced GI disorders.

• Diets that promote sound gut health care.

• How nutrient-gene interactions may alter gastrointestinal conditions.

• How nutrition can help patients with gastroesophageal reflux disease (GERD), IBS, IBD, FGIDs and mast cell activation syndrome.

• Implementing nutrition management therapies.

Join like-minded practitioners and industry counterparts in Freston’s intimate environment designed to foster learning, networking, and engagement. Registration is open and early bird rates are in effect through June 5. Learn more by visiting freston.gastro.org

[email protected]

On April 12, FDA issued a safety communication releasing new information on the duodenoscope contamination rate from postmarket surveillance studies and medical device reports. While the outlook has improved significantly since this issue first arose in 2015, we are not yet at our goal of zero device-associated infections.

AGA encourages all members to stay vigilant when it comes to duodenoscope reprocessing and strictly adhere to the manufacturer’s reprocessing and maintenance instructions.

In the safety communication, FDA reports:

• In the past 6 months, three people died and 45 people developed infections from contaminated endoscopes.

• Results from sampling studies show up to 5.4% of all properly collected samples tested positive for “high concern” organisms. “High concern” bacteria are more often associated with disease, such as E. coli or Staphylococcus aureus.

• Additionally, up to 3.6% of properly collected samples tested positive for low to moderate concern organisms; while these organisms don’t usually lead to dangerous infections, they are indicative of a reprocessing failure.

Jeff Shuren, MD, director of the Center for Devices and Radiological Health at FDA, also issued a communication on continued efforts to assess duodenoscope contamination risk. Dr. Shuren puts this new data into perspective:

“While the current contamination rates we’re seeing in the postmarket studies show the need for improvement, I want to emphasize that an individual patient’s risk of acquiring infection from an inadequately reprocessed medical device remains relatively low given the large number of such devices in use.”

The AGA Center for GI Innovation and Technology (CGIT) continuously monitors this issue and engages with industry and FDA on efforts that will help us reach our goal of zero device-transmitted infections to our patients.

“We continually meet with industry partners, just as recently as last week at the AGA Tech Summit, to understand how they are innovating to reduce the risk of potential infection. We are also in close communication with FDA and other key stakeholders. We all have a role in preventing device-transmitted infections, and we don’t take our role lightly,” added V. Raman Muthusamy, MD, AGAF, FACG, FASGE, chair of the AGA CGIT.
 

[email protected]

On April 12, FDA issued a safety communication releasing new information on the duodenoscope contamination rate from postmarket surveillance studies and medical device reports. While the outlook has improved significantly since this issue first arose in 2015, we are not yet at our goal of zero device-associated infections.

AGA encourages all members to stay vigilant when it comes to duodenoscope reprocessing and strictly adhere to the manufacturer’s reprocessing and maintenance instructions.

In the safety communication, FDA reports:

• In the past 6 months, three people died and 45 people developed infections from contaminated endoscopes.

• Results from sampling studies show up to 5.4% of all properly collected samples tested positive for “high concern” organisms. “High concern” bacteria are more often associated with disease, such as E. coli or Staphylococcus aureus.

• Additionally, up to 3.6% of properly collected samples tested positive for low to moderate concern organisms; while these organisms don’t usually lead to dangerous infections, they are indicative of a reprocessing failure.

Jeff Shuren, MD, director of the Center for Devices and Radiological Health at FDA, also issued a communication on continued efforts to assess duodenoscope contamination risk. Dr. Shuren puts this new data into perspective:

“While the current contamination rates we’re seeing in the postmarket studies show the need for improvement, I want to emphasize that an individual patient’s risk of acquiring infection from an inadequately reprocessed medical device remains relatively low given the large number of such devices in use.”

The AGA Center for GI Innovation and Technology (CGIT) continuously monitors this issue and engages with industry and FDA on efforts that will help us reach our goal of zero device-transmitted infections to our patients.

“We continually meet with industry partners, just as recently as last week at the AGA Tech Summit, to understand how they are innovating to reduce the risk of potential infection. We are also in close communication with FDA and other key stakeholders. We all have a role in preventing device-transmitted infections, and we don’t take our role lightly,” added V. Raman Muthusamy, MD, AGAF, FACG, FASGE, chair of the AGA CGIT.
 

[email protected]

On April 12, FDA issued a safety communication releasing new information on the duodenoscope contamination rate from postmarket surveillance studies and medical device reports. While the outlook has improved significantly since this issue first arose in 2015, we are not yet at our goal of zero device-associated infections.

AGA encourages all members to stay vigilant when it comes to duodenoscope reprocessing and strictly adhere to the manufacturer’s reprocessing and maintenance instructions.

In the safety communication, FDA reports:

• In the past 6 months, three people died and 45 people developed infections from contaminated endoscopes.

• Results from sampling studies show up to 5.4% of all properly collected samples tested positive for “high concern” organisms. “High concern” bacteria are more often associated with disease, such as E. coli or Staphylococcus aureus.

• Additionally, up to 3.6% of properly collected samples tested positive for low to moderate concern organisms; while these organisms don’t usually lead to dangerous infections, they are indicative of a reprocessing failure.

Jeff Shuren, MD, director of the Center for Devices and Radiological Health at FDA, also issued a communication on continued efforts to assess duodenoscope contamination risk. Dr. Shuren puts this new data into perspective:

“While the current contamination rates we’re seeing in the postmarket studies show the need for improvement, I want to emphasize that an individual patient’s risk of acquiring infection from an inadequately reprocessed medical device remains relatively low given the large number of such devices in use.”

The AGA Center for GI Innovation and Technology (CGIT) continuously monitors this issue and engages with industry and FDA on efforts that will help us reach our goal of zero device-transmitted infections to our patients.

“We continually meet with industry partners, just as recently as last week at the AGA Tech Summit, to understand how they are innovating to reduce the risk of potential infection. We are also in close communication with FDA and other key stakeholders. We all have a role in preventing device-transmitted infections, and we don’t take our role lightly,” added V. Raman Muthusamy, MD, AGAF, FACG, FASGE, chair of the AGA CGIT.
 

[email protected]

Rep. Ruiz was a virtually unknown candidate and defeated then incumbent Mary Bono, R-CA, for the seat that represents Coachella Valley and Palm Springs. Rep. Ruiz is the son of migrant farmers from Mexico who went on to medical school and became the first Latino to receive three graduate degrees from Harvard — a medical degree, a masters of public policy, and a masters of public health. Rep. Ruiz is an emergency physician by training and AGA got to know him early in his congressional career and provided support for his initiatives that aligned with our policy priorities and support through AGA PAC.

When Rep. Ruiz was elected to Congress, the Democrats were in the minority in the House and as a freshman member in the minority, did not yield a lot of power and influence. However, AGA continued to work with Rep. Ruiz in garnering his support for repealing the Independent Payment Advisory Board (IPAB) that was created under the Affordable Care Act (ACA) — it was charged with making budgetary decisions for the Medicare program that would have disproportionately impacted physicians. Rep. Ruiz was willing to work with Republicans to support legislation to repeal IPAB; Congress eventually repealed it in the last Congress.

AGA also worked with Rep. Ruiz in support of increasing access to colorectal cancer screening especially for underrepresented minorities and he has been a strong supporter of the Removing Barriers to Colorectal Cancer Screening Act that would fix the current Medicare screening colonoscopy coinsurance problem that disproportionately impacts poorer Medicare beneficiaries who lack supplemental coverage.

Recently, AGA has been working closely with Rep. Ruiz as he champions an issue that impacts GI patients with inflammatory bowel disease and their ability to access the treatment that their doctor recommends. Rep. Ruiz has introduced H.R. 2279, the Safe Step Act, legislation that would provide a clear, transparent, and easily accessible appeals process for physicians and their patients when subject to step therapy protocols. Step therapy, also known as “fail first,” requires patients to try and fail one or more medications before the insurer will provide coverage for the therapy that their doctor thinks is the best to manage their condition. The Safe Step Act would not eliminate step therapy but would provide some common sense guardrails for patients and reasonable exceptions for patients who would be harmed if subjected to such a policy.

Because of AGA PAC’s and other physician organizations’ PAC support for Rep. Ruiz, he was able to secure a seat on the highly coveted Energy and Commerce Committee and its Health Subcommittee. The Committee has jurisdiction over all public health programs such as NIH, CDC, FDA, and Medicare Part B which is all physician services. Given Rep. Ruiz’s background and the committee position he holds, he is well-suited to continue to help champion AGA’s policy priorities and those of all organized medicine.

Over the years, Rep. Ruiz has spoken to AGA members at our annual Advocacy Day on the importance of physicians being involved politically and also in advocacy. He has also met with AGA Government Affairs Committee member Gaurav Singhvi, MD, in the district on issues important to the gastroenterology community and our patients.

AGA looks forward to working with Rep. Ruiz to continue to ensure that patients have access to specialty care, that the administrative burdens that physicians face like prior authorization are reduced, we continue to invest in research, and that we continue to train the next generation of GIs.

[email protected]

Rep. Ruiz was a virtually unknown candidate and defeated then incumbent Mary Bono, R-CA, for the seat that represents Coachella Valley and Palm Springs. Rep. Ruiz is the son of migrant farmers from Mexico who went on to medical school and became the first Latino to receive three graduate degrees from Harvard — a medical degree, a masters of public policy, and a masters of public health. Rep. Ruiz is an emergency physician by training and AGA got to know him early in his congressional career and provided support for his initiatives that aligned with our policy priorities and support through AGA PAC.

When Rep. Ruiz was elected to Congress, the Democrats were in the minority in the House and as a freshman member in the minority, did not yield a lot of power and influence. However, AGA continued to work with Rep. Ruiz in garnering his support for repealing the Independent Payment Advisory Board (IPAB) that was created under the Affordable Care Act (ACA) — it was charged with making budgetary decisions for the Medicare program that would have disproportionately impacted physicians. Rep. Ruiz was willing to work with Republicans to support legislation to repeal IPAB; Congress eventually repealed it in the last Congress.

AGA also worked with Rep. Ruiz in support of increasing access to colorectal cancer screening especially for underrepresented minorities and he has been a strong supporter of the Removing Barriers to Colorectal Cancer Screening Act that would fix the current Medicare screening colonoscopy coinsurance problem that disproportionately impacts poorer Medicare beneficiaries who lack supplemental coverage.

Recently, AGA has been working closely with Rep. Ruiz as he champions an issue that impacts GI patients with inflammatory bowel disease and their ability to access the treatment that their doctor recommends. Rep. Ruiz has introduced H.R. 2279, the Safe Step Act, legislation that would provide a clear, transparent, and easily accessible appeals process for physicians and their patients when subject to step therapy protocols. Step therapy, also known as “fail first,” requires patients to try and fail one or more medications before the insurer will provide coverage for the therapy that their doctor thinks is the best to manage their condition. The Safe Step Act would not eliminate step therapy but would provide some common sense guardrails for patients and reasonable exceptions for patients who would be harmed if subjected to such a policy.

Because of AGA PAC’s and other physician organizations’ PAC support for Rep. Ruiz, he was able to secure a seat on the highly coveted Energy and Commerce Committee and its Health Subcommittee. The Committee has jurisdiction over all public health programs such as NIH, CDC, FDA, and Medicare Part B which is all physician services. Given Rep. Ruiz’s background and the committee position he holds, he is well-suited to continue to help champion AGA’s policy priorities and those of all organized medicine.

Over the years, Rep. Ruiz has spoken to AGA members at our annual Advocacy Day on the importance of physicians being involved politically and also in advocacy. He has also met with AGA Government Affairs Committee member Gaurav Singhvi, MD, in the district on issues important to the gastroenterology community and our patients.

AGA looks forward to working with Rep. Ruiz to continue to ensure that patients have access to specialty care, that the administrative burdens that physicians face like prior authorization are reduced, we continue to invest in research, and that we continue to train the next generation of GIs.

[email protected]

Rep. Ruiz was a virtually unknown candidate and defeated then incumbent Mary Bono, R-CA, for the seat that represents Coachella Valley and Palm Springs. Rep. Ruiz is the son of migrant farmers from Mexico who went on to medical school and became the first Latino to receive three graduate degrees from Harvard — a medical degree, a masters of public policy, and a masters of public health. Rep. Ruiz is an emergency physician by training and AGA got to know him early in his congressional career and provided support for his initiatives that aligned with our policy priorities and support through AGA PAC.

When Rep. Ruiz was elected to Congress, the Democrats were in the minority in the House and as a freshman member in the minority, did not yield a lot of power and influence. However, AGA continued to work with Rep. Ruiz in garnering his support for repealing the Independent Payment Advisory Board (IPAB) that was created under the Affordable Care Act (ACA) — it was charged with making budgetary decisions for the Medicare program that would have disproportionately impacted physicians. Rep. Ruiz was willing to work with Republicans to support legislation to repeal IPAB; Congress eventually repealed it in the last Congress.

AGA also worked with Rep. Ruiz in support of increasing access to colorectal cancer screening especially for underrepresented minorities and he has been a strong supporter of the Removing Barriers to Colorectal Cancer Screening Act that would fix the current Medicare screening colonoscopy coinsurance problem that disproportionately impacts poorer Medicare beneficiaries who lack supplemental coverage.

Recently, AGA has been working closely with Rep. Ruiz as he champions an issue that impacts GI patients with inflammatory bowel disease and their ability to access the treatment that their doctor recommends. Rep. Ruiz has introduced H.R. 2279, the Safe Step Act, legislation that would provide a clear, transparent, and easily accessible appeals process for physicians and their patients when subject to step therapy protocols. Step therapy, also known as “fail first,” requires patients to try and fail one or more medications before the insurer will provide coverage for the therapy that their doctor thinks is the best to manage their condition. The Safe Step Act would not eliminate step therapy but would provide some common sense guardrails for patients and reasonable exceptions for patients who would be harmed if subjected to such a policy.

Because of AGA PAC’s and other physician organizations’ PAC support for Rep. Ruiz, he was able to secure a seat on the highly coveted Energy and Commerce Committee and its Health Subcommittee. The Committee has jurisdiction over all public health programs such as NIH, CDC, FDA, and Medicare Part B which is all physician services. Given Rep. Ruiz’s background and the committee position he holds, he is well-suited to continue to help champion AGA’s policy priorities and those of all organized medicine.

Over the years, Rep. Ruiz has spoken to AGA members at our annual Advocacy Day on the importance of physicians being involved politically and also in advocacy. He has also met with AGA Government Affairs Committee member Gaurav Singhvi, MD, in the district on issues important to the gastroenterology community and our patients.

AGA looks forward to working with Rep. Ruiz to continue to ensure that patients have access to specialty care, that the administrative burdens that physicians face like prior authorization are reduced, we continue to invest in research, and that we continue to train the next generation of GIs.

[email protected]

As the Vascular Annual Meeting approaches, we hope you are gearing up for a great few days of vascular programming, networking, receptions and fun! We invite you to share meeting details with your peers and colleagues on social media to generate excitement and increase attendance. To help you do this, we've put together a social media kit with directions, example posts and images you may use to spread the word about VAM. Start posting with directions listed here.

As the Vascular Annual Meeting approaches, we hope you are gearing up for a great few days of vascular programming, networking, receptions and fun! We invite you to share meeting details with your peers and colleagues on social media to generate excitement and increase attendance. To help you do this, we've put together a social media kit with directions, example posts and images you may use to spread the word about VAM. Start posting with directions listed here.

As the Vascular Annual Meeting approaches, we hope you are gearing up for a great few days of vascular programming, networking, receptions and fun! We invite you to share meeting details with your peers and colleagues on social media to generate excitement and increase attendance. To help you do this, we've put together a social media kit with directions, example posts and images you may use to spread the word about VAM. Start posting with directions listed here.

A community has opened specifically for our PA Section members on SVSConnect. This community is meant to provide a private space for vascular PAs to engage and collaborate with one another. Members will be able to have in depth discussions surrounding important issues including case complications and surgical procedures, research projects, wellness topics and much more. If you haven’t logged into SVSConnect yet, what are you waiting for? All you need are your SVS log in credentials to get started. Email [email protected] or call 312-334-2300 with questions. Sign in here.

A community has opened specifically for our PA Section members on SVSConnect. This community is meant to provide a private space for vascular PAs to engage and collaborate with one another. Members will be able to have in depth discussions surrounding important issues including case complications and surgical procedures, research projects, wellness topics and much more. If you haven’t logged into SVSConnect yet, what are you waiting for? All you need are your SVS log in credentials to get started. Email [email protected] or call 312-334-2300 with questions. Sign in here.

A community has opened specifically for our PA Section members on SVSConnect. This community is meant to provide a private space for vascular PAs to engage and collaborate with one another. Members will be able to have in depth discussions surrounding important issues including case complications and surgical procedures, research projects, wellness topics and much more. If you haven’t logged into SVSConnect yet, what are you waiting for? All you need are your SVS log in credentials to get started. Email [email protected] or call 312-334-2300 with questions. Sign in here.

Requirements for starting a vascular surgery training program have been lightened – you no longer need to have a general surgery residency at your institution and faculty requirements are in review. Because of this, SVS members are available to encourage and assist with the formation of new vascular surgery training programs. From 9:30 a.m. to 10:30 a.m. on Friday, June 14, at the Vascular Annual Meeting, an information session will be held for those interested in establishing a vascular training program. If you’re heading to the meeting in June, stop by National Harbor 4 Room at the Gaylord National to hear more about this. Register for VAM today.

Requirements for starting a vascular surgery training program have been lightened – you no longer need to have a general surgery residency at your institution and faculty requirements are in review. Because of this, SVS members are available to encourage and assist with the formation of new vascular surgery training programs. From 9:30 a.m. to 10:30 a.m. on Friday, June 14, at the Vascular Annual Meeting, an information session will be held for those interested in establishing a vascular training program. If you’re heading to the meeting in June, stop by National Harbor 4 Room at the Gaylord National to hear more about this. Register for VAM today.

Requirements for starting a vascular surgery training program have been lightened – you no longer need to have a general surgery residency at your institution and faculty requirements are in review. Because of this, SVS members are available to encourage and assist with the formation of new vascular surgery training programs. From 9:30 a.m. to 10:30 a.m. on Friday, June 14, at the Vascular Annual Meeting, an information session will be held for those interested in establishing a vascular training program. If you’re heading to the meeting in June, stop by National Harbor 4 Room at the Gaylord National to hear more about this. Register for VAM today.

At the Annual Business Meeting, 12 to 1:30 p.m. Saturday, June 15, SVS members (Active, Seniors and/or Distinguished Fellows) will be asked to elect individuals to fill the positions of Secretary and Vice President and then approve the full slate of SVS Officers for 2019-20. The Nominating Committee unanimously identified one person felt to be uniquely qualified to assume the position of Vice President; as in the past, that candidate will be announced at the meeting. Members will select among three highly qualified candidates for Secretary: Keith Calligaro, Michael Conte and Amy Reed. Find information from each of them here. 

At the Annual Business Meeting, 12 to 1:30 p.m. Saturday, June 15, SVS members (Active, Seniors and/or Distinguished Fellows) will be asked to elect individuals to fill the positions of Secretary and Vice President and then approve the full slate of SVS Officers for 2019-20. The Nominating Committee unanimously identified one person felt to be uniquely qualified to assume the position of Vice President; as in the past, that candidate will be announced at the meeting. Members will select among three highly qualified candidates for Secretary: Keith Calligaro, Michael Conte and Amy Reed. Find information from each of them here. 

At the Annual Business Meeting, 12 to 1:30 p.m. Saturday, June 15, SVS members (Active, Seniors and/or Distinguished Fellows) will be asked to elect individuals to fill the positions of Secretary and Vice President and then approve the full slate of SVS Officers for 2019-20. The Nominating Committee unanimously identified one person felt to be uniquely qualified to assume the position of Vice President; as in the past, that candidate will be announced at the meeting. Members will select among three highly qualified candidates for Secretary: Keith Calligaro, Michael Conte and Amy Reed. Find information from each of them here.